Brain Cancer

IRB #06-231- Phase I/II trial of maximal resection, local radiation boost with concomitant temozolomide, followed by external beam radiation with concomitant temozolomide for the treatment of newly diagnosed glioblastoma multiforme

Breast Cancer

IRB # 06-233- Phase 3 study of SU011248 in combination with paclitaxel vs. bevacizumab with paclitaxel in the 1st line setting for advanced disease in patients with breast cancer [Pfizer A6181094]

IRB # 07-035- A treatment protocol for patients continuing from the prior SU011248 Protocol [Pfizer A6181078]

IRB # 06-275- Program for the Assessment of Clinical Cancer tests (PACCT-1): Trial Assigning Individualized Options for Treatment: THE TAILORX TRIAL [ECOG]

IRB # 06-206- Randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1 mg) in postmenopausal women with clinical stage II and III estrogen receptor positive breast cancer [ACOSOG Z1031]

IRB # Pending-  A randomized phase III trial comparing a neoadjuvant regimen of FEC-75 followed by paclitaxel plus trastuzumab with a neoadjuvant regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with palpable and operable Breast Cancer [ACOSOG Z1041]    

IRB # Pending- An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer [BO20289 - Beatrice]   

IRB # Pending- A phase I/II clinical trial of the hypomethylating agent azacitadine (Vidaza) with the nanoparticle albumin bound paclitaxel (Abraxane) in the treatment of patients with advanced or metastatic solid tumors and breast cancer 

Colon/Rectal Cancer

IRB #_08-070- A randomized, phase 2B study of sunitinib plus oxaliplatin, 5-flourouracil and leucovorin (FOLFOX) versus bevacizumab plus FOLFOX as first-line treatment in patients with mestastatic colorectal cancer   [A6181104]

Melanoma

IRB # 07-116- A phase II study of an anti-tumor immunotherapy regimen comprised of pegylated Interferon-α 2b (PEG-INTRON®) and HyperAcute® melanoma vaccine for patients with stage IIIB, IIIC, recurrent and/or refractory melanoma and stage IV melanoma [Investigator-Initiated; NewLink Genetics, Schering-Plough]

IRB # 07-226- A multicenter, randomized, double-blind study of dacarbazine with or without Genasense® (oblimersen®, anti-Bcl2 agent) in chemotherapy-naive patients with advanced melanoma and non-elevated, normal LDH levels (The AGENDA Trial). [Genta]

IRB # 07-264- Phase III randomized adjuvant study of high-dose interferon α-2b (INTRON-A®) therapy in patients with Stage II or III Melanoma [ECOG-1697]

Lung Cancer

IRB # 06-276- A randomized, double-blind, phase II study of erlotinib with or without SU011248 in the treatment of metastatic non-small cell lung cancer [Pfizer A6181058]

IRB # 07-035- A treatment protocol for patients continuing from a prior SU011248 protocol [Pfizer A6181078]

Follicular B-Cell Non-Hodgkin’s Lymphoma

IRB # Pending- An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non-Hodgkin’s Lymphoma [Wyeth]

Pancreatic Cancer

IRB # 05-184- A randomized, phase II, study of TNFerade biologic with 5-FU and radiation therapy for 1st-line treatment of unresectable, locally advanced pancreatic cancer [Genvec]

IRB # 07-162- A randomized double-blind phase III study of RAD001 + best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumors [Novartis]

IRB # 07-150- A Phase III trial comparing GV1001 and gemcitabine in sequential combination to gemcitabine monotherapy in advanced unresectable pancreatic cancer [Pharmexa]

Endometrial Cancer

IRB # 08-069 - A Phase II Study of Paclitaxel and Carboplatin in Patients with Intermediate-Risk Adenocarcinoma of the Endometrium

Ovarian Cancer

IRB # Pending- A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal Cancer [GOG 0218] 

Cervical Cancer

IRB # Pending- A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis  [GOG 0219]

Quality of Life

IRB # 06-198- Risks and outcomes of mucositis in patients with breast, colorectal, head/neck, non-small cell lung or ovarian cancer

IRB # 05-229- A multiple-dose, non-randomized, open-label, multicenter study to evaluate the long-term safety and efficacy of EN3267 in the treatment of breakthrough pain in cancer patients

IRB # 07-034- An observational study of Avastin (bevacizumab) in combination with chemotherapy for the treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung cancer (excluding predominantly squamous cell histology), or locally recurrent or metastatic breast cancer [Genentech]

IRB # 07-034 - AVF3991n:  An observational study of AVASTINâ (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer and locally advanced or metastatic non-small cell lung cancer (excluding predominant squamous cell histology) [ARIES]